tbuckley/cabot-search huggingface dataset:
Lactate Clearance and Central Venous Oxygen Saturation in Early Sepsis—Reply
Authors: Alan E. Jones
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of calcium channel blockers as antihypertensives in relation to mortality. A population based observational study.
Authors: Gunnar Lindberg, Ulf Lindblad, Bent Low-Larsen, Juan Merlo, Arne Melander, Lennart Rastam
Journal: Circulation (2001)

P51 The beneficial effect of pharmacological treatment of hypertension is well established. However, the outcome may depend on the specific antihypertensive drug used. This study, aimed to compare mortality in users of calcium channel blockers (CCBs) with that in users of other antihypertensive drugs (AHDs), includes 719 patients on antihypertensive drugs at an outpatient clinic in primary care in 1989-90. They were classified as users of CCBs (mostly felodipine) or users of other ADHs according to status at inclusion. Co-morbidity, systolic blood pressure, and smoking data were derived from standardised patient records. The Swedish mortality register was used to follow patients until death or until the end of 1995. Odds ratios were calculated by Cox regression analysis (the table). Although adjustment was made for confounders, mortality was higher in CCB users. This adds support to the view that CCBs may be inferior to other ADHs in reducing mortality when used to treat hypertension and should not be considered a first-line drug. Table 1.
BOOK REVIEW
Authors: D. V. SPICER
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article BOOK REVIEW Get access Estrogen and Breast Cancer: a Warning to Women Carol Ann Rinzler . New York : Macmillan , 1993 . 233 pp., illus. $22. ISBN 0-02-603491-3 DARCY V. SPICER DARCY V. SPICER M.D. Kenneth Norris, Jr., Cancer Center University of Southern California1441 Eastlake Ave. Los Angeles, CA 90033 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 15, 3 August 1994, Pages 1170–1171, https://doi.org/10.1093/jnci/86.15.1170 Published: 03 August 1994
The Resurgence Of Measles In The United States, 1989-1990
Authors: W. Atkinson
Journal: Annual Review of Medicine (1992)

After almost a decade of relatively few reported cases, a major resurgence of measles occurred in the United States in 1989-1990. The increase primarily involved unvaccinated racial and ethnic minority children less than five years of age residing in inner-city areas. Outbreaks of measles among vaccinated school-aged children continued to occur but had less impact than outbreaks among preschool-aged children. Efforts to prevent measles must be aimed at improving age-specific measles vaccination coverage among preschool-aged children, and implementation of a two-dose measles strategy among school-aged children.
A phase II, open-label pilot study evaluating the safety and activity of nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).
Authors: Hiral D. Parekh, David L. DeRemer, Kathryn Hitchcock, Susan P. McGorray, Allison Allegra, Alisha Daniels, Z. Hugh Fan, Carmen Joseph Allegra, Robert Zlotecki, Steven J. Hughes, Jessica L Cioffi, Jose Gilberto Trevino, Thomas J. George
Journal: Journal of Clinical Oncology (2019)

TPS476 Background: Neoadjuvant treatment for borderline resectable pancreatic cancer (PCa) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demonstrated feasibility and effectiveness of the FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin and irinotecan) regimen in the perioperative setting. However, FOLFIRINOX often requires dose modifications, delays and growth factor support due to excessive toxicity which can complicate care delivery when given neoadjuvantly. Irinotecan liposomal injection (Nal-IRI) is FDA approved with a very tolerable safety profile in refractory metastatic PCa. The current study aims to substitute Nal-IRI for traditional irinotecan in the standard FOLFIRINOX regimen and demonstrate safe and effective delivery in the neoadjuvant setting. Methods: This phase II, open-label, single-arm study targets patients with borderline resectable PCa without metastatic disease. Other key eligibility criteria include age ≥ 18 years, measurable disease by RECIST v1.1, adequate cardiac, renal, hepatic function, and Eastern Cooperative Oncology Group performance status of 0 to 1. Patients receive FOLFNal-IRINOX regimen as per table every two weeks for four months followed by disease reassessment. Patients who remain surgical candidates will undergo surgical resection within four to eight weeks following last dose of therapy. The primary endpoint is to assess safety and feasibility of regimen in perioperative setting. Secondary endpoints include R0 resection rate, clinical, biochemical and radiological response rate and patient-reported quality of life as measured by the NCI validated FACT-G scale. Enrollment continues to a maximum of 28 evaluable patients to demonstrate a reduction in historical 30 day postoperative complication rate. FOLFNal-IRINOX regimen. Clinical trial information: NCT03483038. [Table: see text]
Morbo a Grattamento de Catto con Encephalopathia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Students' Guide to Operative Surgery.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dysregulated MicroRNA Affects Pathways and Targets of Biological Relevance in Nasal-Type Natural Killer/T-Cell Lymphoma
Authors: Wee-Joo Chng, Junli Yan, Gaofeng Huang, Viknesvaran Selvarajan, Jim Tay, Baohong Lin, Chonglei Bi, Joy Tan, Siok-Bian Ng
Journal: Blood (2011)
RESPONSE: Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Authors: F. Saad
Journal: JNCI Journal of the National Cancer Institute (2004)

The results of the well-conducted trial by Saad et al. (1) have prompted many to consider routine use of zoledronic acid to reduce the incidence of skeletal-related events in minimally symptomatic or asymptomatic men with hormone-refractory prostate cancer.This is a somewhat troublesome proposition, because all men in this situation are not at risk of a skeletal-related event.In the placebo arm of the trial (1), the rate of skeletal-related events was 44.2%, and thus more than half the men participating in the trial never experienced a skeletal-related event.Higher rates of fatigue, anemia, myalgia, fever, lower limb edema, dizziness, and weight loss were reported by men who received zoledronic acid than by men who received placebo.Thus, there is a good rationale for avoiding this treatment in men at little risk for a skeletal-related event.Uni-and multivariable analyses of baseline patient characteristics and treatment received are usually included in reports of large, randomized trials.Typically these analyses identify independent predictors of the primary outcome and adjust the treatment effect for chance imbalances in these predictors, increasing the precision of the treatment effect (2).Compared with men who received placebo, men who received zoledronic acid at 4 mg had fewer prior skeletal-related events (30.8% versus 37.5%) and had longer median survival (546 days versus 464 days), suggesting subtle differences between these groups at baseline that may have influenced the
Cytotoxic antibody complicating platelet support in acute leukemia. Response to chemotherapy
Authors: D. Green
Journal: JAMA (1976)

Lymphocytotoxic or thrombocytolytic antibodies were detected in 11 of 25 thrombocytopenic patients receiving repeated platelet transfusions. Platelet survival times were reduced in these patients (half-life [T/2], 32 hours) as compared to patients without antibody (T/2, 51 hours,<i>P</i>&lt;.05). In one woman with acute myeloblastic leukemia and a potent platelet antibody, combination chemotherapy resulted in a profound decrease in circulating γ globulin and concurrent disappearance of the cytotoxic antibody. The survival of transfused platelets in this patient was dramatically improved, and bleeding was controlled. (<i>JAMA</i>236:1044-1046, 1976)
Scientific Thinking
Authors: Magda Osman
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influenza Vaccine: Preliminary Statement
Journal: Annals of Internal Medicine (1978)

Diagnosis and Treatment1 September 1978Influenza Vaccine: Preliminary StatementRecommendation of the Public Health Service Advisory Committee on Immunization PracticesAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-3-373 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractThe primary influenza vaccine for 1978-79 will be an inactivated trivalent preparation of antigens representative of the three currently prevalent influenza viruses. A monovalent vaccine will also be produced if needed for optimum immunization of any population group. Annual vaccination is recommended for persons of all ages who have various chronic conditions. Physicians should evaluate pregnant women for influenza immunization according to the criteria applied to other persons.Selected Bibliography1. Clinical studies of influenza vaccines—1976. (A conference held at the National Institutes of Health, Bethesda, Maryland, 20-21 January 1977.) J Infect Dis 136(suppl):S345-S742, 1977 Google Scholar2. DOWDLECOLEMANGREGG WMM: Natural history of influenza type A in the United States, 1957-1972. Prog Med Virol 17:91-135, 1974 MedlineGoogle Scholar3. EICKHOFF T: Immunization against influenza: rationale and recommendations. J Infect Dis 123:446-454, 1971 CrossrefMedlineGoogle Scholar4. KILBOURNE E (ed.): The Influenza Viruses and Influenza. New York, Academic Press, 1975 Google Scholar5. LENEMAN F: The Guillain-Barré syndrome. Definition, etiology, and review of 1, 100 cases. Arch Intern Med 118:139-144, 1966 CrossrefMedlineGoogle Scholar6. PARKMANGALASSOTOPNOBLE PGFG: Summary of clinical trials of influenza vaccines. J Infect Dis 134:100-107, 1976 CrossrefGoogle Scholar7. WRIGHTDOLINLA MONTAGNE PRJ: Summary of clinical trials of influenza vaccines. II. J Infect Dis 134:633-638, 1976 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: ▸From the Center for Disease Control, U.S. Department of Health, Education, and Welfare; Atlanta, Georgia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDevelopment of next generation hemagglutinin-based broadly protective influenza virus vaccinesStudio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anniInfluenza Vaccination in Patients with Chronic Renal FailureReview Article : Implementing Preventive Care in Clinical Practice 1 September 1978Volume 89, Issue 3Page: 373-374KeywordsAntigensInfluenza virusesPregnancyVaccines ePublished: 1 December 2008 Issue Published: 1 September 1978 PDF downloadLoading ...
Petriellidium boydii (Allescheria boydii)
Authors: Hanna A. Saadah
Journal: JAMA (1981)

<i>PETRIELLIDIUM boydii</i>(formerly<i>Allescheria boydii</i>) is a ubiquitous soil fungus<sup>1</sup>that is a common cause of Madura foot in North America.<sup>2</sup>It has also been reported to cause disseminated disease,<sup>3,4</sup>posttraumatic bone and soft-tissue infections,<sup>1,4</sup>endocarditis,<sup>5</sup>sinusitis,<sup>6</sup>meningoencephalitis,<sup>4</sup>brain, thyroid, renal, prostate, or myocardial abscesses,<sup>3,4,7</sup>parotitis,<sup>8</sup>otomycosis,<sup>8</sup>and endophthalmitis.<sup>4</sup>Pulmonary disease is rare and usually involves apical intracavitary (mycetoma) or intrabronchial growth of the fungus with secondary pulmonary tissue reaction.<sup>2,4,7,8</sup>Because this fungus has a low pathogenicity for man, necrotizing pneumonia has been reported mainly in patients whose immunity has been severely compromised.<sup>4,7,8</sup>We believe this is the first case report of a truly invasive<i>P boydii</i>necrotizing pneumonia in an apparently normal host.<sup>9</sup> <h3>Report of a Case</h3> A 32-year-old woman was in good health until January 1978, when fever and a productive cough developed. The chest
Human Monstrosities.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ulceration by oral ferrous sulfate
Authors: T. R. Abbarah
Journal: JAMA (1976)

WHEN ingested in toxic proportions, ferrous sulfate is known to have a corrosive effect on the gastric mucosa, with necrosis and petechial hemorrhages.<sup>1-3</sup>To the best of our knowledge, there are no previous reports of such effects on the hypopharynx or esophageal mucosa. We report a case of ulceration and swelling of the hypopharynx and cervical esophagus after a single 525-mg ferrous sulfate tablet became lodged in the hypopharynx. <h3>Report of a Case</h3> An 89-year-old woman entered the emergency department complaining of dysphagia after taking a ferrous pill 2 1/2 hours earlier. There was severe edema of the arytenoids and swelling in the aryepiglottic fold and piriform sinus on the left. The vocal cords appeared normal, and no foreign body was visualized. Lateral xerograms of the neck showed considerable swelling of the aryepiglottic folds, arytenoids, and prevertebral soft tissue in the area of the hypopharynx cervical esophagus. A barium
Leads from the MMWR. Foodborne botulism--Illinois
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chromodiagnosis by the Two-Color Test in Internal, Particularly Liver Diseases
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts
Journal: Journal of Clinical Investigation (1974)

= Emeritus or senior member a marked fall in the glomerular capillary ultrafiltration coefficient, Kf, to a mean value of 0.03 nl/s mm Hg), considerably lower than that found recently for the normal rat (0.08 nl/s mm Hg).Thus, despite extensive glomerular injury, evidenced morpho- logically, and by the low Kf, GFR remained normal.This maintenance of GFR resulted from increases in AP and glomerular plasma flow, both of which increase the net driving force for filtration, and thereby compensate for the reduction in Kf.
Migrainelike headache and cocaine use
Authors: S. L. Satel
Journal: JAMA (1989)

Migrainelike headache is a sequela of cocaine use. This finding expands the range of neurological complications of cocaine use and is consistent with the potential role of serotonin in the development of migraine. In these subjects, the desire to avoid the cocaine-induced headache eventually became part of the resolve to quit use. (<i>JAMA</i>. 1989;261:2995-2996)